BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, circBA9.3 increases both ABL1 and BCR-ABL1 expression and reduces sensitivity of cancer cells to imatinib, suggesting that it is involved in CML resistance (129).